After Sell-Off, Dabur Pharma Promoters Aim At Value Creation Opportunities “Other than Generics”
This article was originally published in PharmAsia News
Executive Summary
MUMBAI - Having sold its generic oncology business to German infusion drugs and clinical nutrition company Fresenius Kabi, Dabur Pharma Founder Anand Burman is looking at a second source of value creation beyond generics